Home > Press > MFIC Corporation Appoints Vice President of Operations and Engineering
Abstract:
MFIC Corporation (OTCBB: MFIC) today announced the appointment of William J. Conroy as Vice President of Operations and Engineering. In this position, Mr. Conroy will have responsibility for the global operations of the Company's Microfluidics equipment business, including product design and engineering, production, quality assurance and quality control, and purchasing. In direct support of MFIC's quality initiative, Mr. Conroy will also assume responsibility for overall systems quality and reliability. Mr. Conroy will report directly to Michael C. Ferrara, Chief Executive Officer.
"Bill is an important addition to the MFIC management team and we
believe that the Company and our customers will greatly benefit from
his extensive experience," said Michael C. Ferrara. "Bill's proven
ability to create highly functioning, quality-driven operating units
and his strong innovation and leadership skills will play a critical
role in MFIC's global growth strategy."
"I'm pleased to be joining MFIC at such an important time in the
Company's history," said William J. Conroy. "I believe MFIC has
substantial opportunity for global growth and I look forward to
working with the team to build an operations organization that is
second to none in terms of innovation, quality and customer focus."
Mr. Conroy brings more than twenty-five years of high-tech product
management, quality control and operations experience to MFIC. Most
recently, he served as Senior Vice President of Production and
Operations at RemoteReality Corporation, which designs and
manufactures products for the military/defense and security business
sectors. Mr. Conroy has also held senior level operations,
manufacturing and quality control positions at Northrop Grumman
(formerly Fibersense Technology Corporation), Karl Storz Endovision,
Circon ACMI and Kohler Company.
####
About MFIC Corporation
MFIC Corporation, through its Microfluidics Division, designs,
manufactures and distributes proprietary high performance
Microfluidizer(R) materials processing and formulation equipment to
the biotechnology, pharmaceutical, chemical, cosmetics/personal care,
and food industries. MFIC applies its more than 20 years of high
pressure processing experience to produce the most uniform and
smallest liquid and suspended solid particles available, and has
provided manufacturing systems for nanoparticle products for more than
15 years.
The Company is a leader in advanced materials processing equipment
for laboratory, pilot scale and manufacturing applications, offering
innovative technology and comprehensive solutions for nanoparticles
and other materials processing and production. More than 3,000 systems
are in use and afford significant competitive and economic advantages
to MFIC equipment customers.
Forward Looking Statement:
Management believes that this release contains forward-looking
statements that are subject to certain risks and uncertainties
including statements relating to our plan to achieve, maintain and/or
increase growth in revenue and/or market share, to achieve, maintain,
and/or increase operating profitability, and/or to achieve, maintain,
and/or increase net operating profitability. Such statements are based
on our current expectations and are subject to a number of factors and
uncertainties that could cause actual results achieved by us to differ
materially from those described in the forward-looking statements. We
caution investors that there can be no assurance that the actual
results or business conditions will not differ materially from those
projected or suggested in such forward-looking statements as a result
of various factors, including but not limited to, the following risks
and uncertainties: (i) whether the performance advantages of our
Microfluidizer materials processing equipment will be realized
commercially or that a commercial market for the equipment will
continue to develop, (ii) whether the timing of orders will
significantly affect quarter to quarter revenues and resulting net
income results for a particular quarter, which may cause increased
volatility in our stock price, (iii) whether we will have access to
sufficient working capital through continued and improving cash flow
from sales and ongoing borrowing availability, the latter being
subject to our ability to maintain compliance with the covenants and
terms of our loan agreement with our senior lender, (iv) whether our
Microfluidics Reaction Technology will be adopted by customers as a
means of producing innovative materials in large quantities, (v)
whether we are able to deploy prototype Microfluidics Reaction
Technology systems for nanoparticle production and then manufacture
and introduce commercial production Microfluidics Reaction Technology
equipment, and (vi) whether we will achieve a greater proportion of
our sales in the future through the sale of advanced processor
production systems.
For more information, please click here
Contacts:
MFIC Corporation
Jack M. Swig
617-969-5452
or
MacDougall Biomedical Communications
Sarah Cavanaugh
781-235-3060
Copyright © MFIC Corporation
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Microfluidics/Nanofluidics
Implantable device shrinks pancreatic tumors: Taming pancreatic cancer with intratumoral immunotherapy April 14th, 2023
Researchers design new inks for 3D-printable wearable bioelectronics: Potential uses include printing electronic tattoos for medical tracking applications August 19th, 2022
Oregon State University research pushes closer to new therapy for pancreatic cancer May 6th, 2022
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Appointments/Promotions/New hires/Resignations/Deaths
Leibniz Prize winner Professor Dr. Oliver G. Schmidt moves to Chemnitz University of Technology: President Professor Dr. Gerd Strohmeier refers to an 'absolute top transfer' September 10th, 2021
JEOL USA Welcomes New Managing Director, Hidetaka Sawada April 19th, 2021
The National Space Society Remembers Ben Bova : NSS Mourns the Loss of a Visionary NSS Leader December 2nd, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||